UNICA IRIS Institutional Research Information System

CARTA, ANNAROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 156.682
NA - Nord America 7.164
AS - Asia 2.751
SA - Sud America 491
AF - Africa 87
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 5
Totale 167.216
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 154.807
US - Stati Uniti d'America 7.050
CN - Cina 1.195
SG - Singapore 927
UA - Ucraina 523
SE - Svezia 431
BR - Brasile 418
DE - Germania 243
GB - Regno Unito 207
FI - Finlandia 159
VN - Vietnam 133
HK - Hong Kong 106
KR - Corea 106
FR - Francia 88
CA - Canada 86
IN - India 48
ES - Italia 38
RU - Federazione Russa 35
NL - Olanda 33
JP - Giappone 29
AR - Argentina 28
AU - Australia 27
IR - Iran 27
PL - Polonia 23
MX - Messico 20
TR - Turchia 20
BD - Bangladesh 19
ZA - Sudafrica 19
AT - Austria 18
IQ - Iraq 17
BE - Belgio 16
EG - Egitto 16
ID - Indonesia 16
PK - Pakistan 14
IE - Irlanda 13
IL - Israele 13
KE - Kenya 13
EC - Ecuador 12
UZ - Uzbekistan 11
CO - Colombia 10
OM - Oman 10
GH - Ghana 9
LT - Lituania 9
NZ - Nuova Zelanda 9
MA - Marocco 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
VE - Venezuela 7
CZ - Repubblica Ceca 6
EU - Europa 5
JO - Giordania 5
KZ - Kazakistan 5
TH - Thailandia 5
AZ - Azerbaigian 4
CH - Svizzera 4
HR - Croazia 4
MU - Mauritius 4
MY - Malesia 4
NP - Nepal 4
TN - Tunisia 4
TW - Taiwan 4
AL - Albania 3
DZ - Algeria 3
GR - Grecia 3
JM - Giamaica 3
PH - Filippine 3
PT - Portogallo 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
BO - Bolivia 2
CI - Costa d'Avorio 2
ET - Etiopia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MM - Myanmar 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 167.211
Salva come PNG Salva come JPEG
Città #
Cagliari 150.736
Uta 3.579
Fairfield 815
Woodbridge 588
Ashburn 516
Chandler 496
Singapore 478
Houston 394
Seattle 351
Wilmington 339
Ann Arbor 327
Boardman 321
Dallas 313
Nyköping 291
Jacksonville 278
Cambridge 266
Beijing 256
Dearborn 207
Santa Clara 112
Shanghai 107
Los Angeles 99
Nanjing 99
Hangzhou 93
Hefei 92
Seoul 88
Boston 84
New York 80
Hong Kong 72
The Dalles 66
Helsinki 65
San Diego 63
Buffalo 54
Guangzhou 37
Ho Chi Minh City 37
Milan 36
Toronto 34
Nanchang 30
Redwood City 28
Shenyang 28
Changsha 27
Hanoi 27
São Paulo 27
London 26
Redondo Beach 26
Munich 24
Norwalk 23
Atlanta 22
Mountain View 22
Dong Ket 20
Hebei 20
Brooklyn 19
Jinan 18
Sassari 18
Tianjin 17
Tokyo 17
Brussels 16
Jiaxing 16
Montreal 16
Verona 16
Assèmini 15
Barcelona 15
Chicago 15
Council Bluffs 15
Frankfurt am Main 15
Warsaw 15
San Mateo 14
Belo Horizonte 13
Phoenix 13
Rio de Janeiro 13
Rome 13
Zhengzhou 13
Amsterdam 11
Nuremberg 11
Orange 11
Orem 11
Tashkent 11
Poplar 10
Vienna 10
Washington 10
Accra 9
Auburn Hills 9
Augusta 9
Columbus 9
Curitiba 9
Dublin 9
Nairobi 9
San Francisco 9
Stockholm 9
Torino 9
Cairo 8
Charlotte 8
Denver 8
Johannesburg 8
Kilburn 8
Lappeenranta 8
Turku 8
Ankara 7
Brasília 7
Cleveland 7
Douglasville 7
Totale 162.800
Salva come PNG Salva come JPEG
Nome #
Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease 5.293
Nematicidal activity of 2-thiophenecarboxaldehyde and methylisothiocyanate from caper (Capparis spinosa) against Meloidogyne incognita 4.592
null 4.110
Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice 3.794
Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease 3.651
The MPTP/probenecid model of progressive Parkinson's disease 3.481
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease 3.403
Role of Adenosine in the basal Ganglia 3.324
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. 3.225
PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests nigrostriatal degeneration in a progressive Parkinson’s disease model. 3.130
A442 PPAR-gamma agonist rosiglitazone inhibits TNF-alpha production by microglia and arrests neurodegeneration in a progressive Parkinson´s disease model 2.977
Microglial phenotypes in Parkinson's disease and animal models of the disease 2.971
Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders 2.934
Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function 2.913
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? 2.827
L-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? 2.771
L dopa chronic treatment increases reactive microglia and tnf- alpha production in the 6-ohda lesioned striatum 2.675
Modulating microglia activity with PPAR-gamma agonists: a promising therapy for Parkinson's disease? 2.597
null 2.592
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats 2.531
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease 2.475
Disease modifying treatment with PPAR-gamma agonist rosiglitazone in a progressive mouse model of Parkinson's disease 2.452
Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease 2.391
Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats 2.240
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease 2.202
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease 2.163
PPAR-GAMMA RECEPTOR AGONIST PREVENTS NEURODEGENERATION AND BEHAVIOURAL DEFICITS IN A CHRONIC MPTP MOUSE MODEL OF PARKINSON’S DISEASE. 2.059
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 2.059
The interrelationship between dopamine and noradrenaline in the prefrontal cortex: From physiology to therapy 1.969
SELECTIVE CHANGES IN DENDRITIC SPINES OF STRIATAL MEDIUM SPINY NEURONS IN A CHRONIC MOUSE MODEL OF PARKINSON'S DISEASE. 1.960
The role of microglia–lymphocyte interaction in PD neuropathology 1.958
PROGRESSIVE DECLINE OF BEHAVIORAL AND BIOCHEMICAL PARAMETERS IN THE CHRONIC MPTP/PROBENECID MOUSE MODEL OF PARKINSON’S DISEASE. 1.922
PPAR-γ: Therapeutic Prospects in Parkinson's Disease. 1.873
null 1.857
Dyskinesia in Parkinson's disease therapy 1.852
PEROXIZOME-PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARG) AGONIST ROSIGLITAZONE COUNTERACTS BEHAVIORAL AND BIOCHEMICAL DEFICITS IN A CHRONIC 1-METHYL-4-PHENIL-1,2,3,4 TETRAHYDROPYRIDINE (MPTP) MOUSE MODEL OF PARKINSON’S DISEASE 1.843
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 1.793
Advances in modelling alpha-synuclein-induced Parkinson's diseases in rodents: virus-based models versus inoculation of exogenous preformed toxic species 1.743
Microglial phagocytosis and its regulation: A therapeutic target in parkinson’s disease? 1.682
null 1.651
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat 1.604
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease 1.552
Farmaci utilizzati nella terapia della Malattia di Parkinson e di altri disturbi motori 1.528
Controversie: Priming dopaminergico nel Parkinson. Il "priming" come modello sperimentale delle discinesie indotte da terapie dopaminergiche sostitutive nella Malattia di Parkinson 1.499
Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model 1.497
Can pioglitazone be potentially useful therapeutically in treating patients with Covid-19? 1.341
Long-term increase in GAD67 mRNA expression in the central amygdala of rats sensitized by drugs and stress 1.299
Adenosine signaling in the basal ganglia 1.273
Caffeine sensitization and cross-sensitization with amphetamine: association to post-synaptic changes in rat striatal neurons 1.219
null 1.194
Metabolomics fingerprint induced by the intranigral inoculation of exogenous human alpha-synuclein oligomers in a rat model of Parkinson’s disease 1.182
The 6-hydroxydopamine model of Parkinson's disease 1.164
The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications 1.152
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease 1.138
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence 1.138
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats 1.133
null 1.108
Modeling Parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers 1.097
Dopamine and adenosine receptor interaction as the basis for the treatment of Parkinson's disease 1.091
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 1.058
Adenosine A2A receptors and Parkinson's disease 1.037
CAFFEINE SESITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST-SYNAPTIC CHANGES IN RAT STRIATAL NEURONS 1.024
null 1.012
CAFFEINE SENSITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION TO POST BUT NOT PRE-SYNAPTIC CHANGES IN RAT STRIATAL NEURON 1.008
null 981
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dyskinesia 948
The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex 944
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression 943
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats 939
Changes in the expression of tonic and phasic neurochemical markers of activity in a rat model of L-DOPA induced dynskinesia 922
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats 897
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? 868
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment 853
null 830
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson’s disease 813
null 801
Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses 774
Modulation of dopamine d1-mediated turning behavior and striatal c-fos expression by the substantia nigra 761
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous L-DOPA delivery in the 6-OHDA model of Parkinson's disease 760
Effect of MK 801 on priming of D-1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen 741
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation 738
“Priming” to dopamine agonist-induced contralateral turning as model of non associative sensitization to the expression of the post-synaptic dopamine message 719
Role of prefrontal cortex dopamine and noradrenaline circuitry in addiction 691
MPTP: Advances from an Evergreen Neurotoxin 686
Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice 678
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats 668
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders 652
GABA(A) receptors mediate orexin-A induced stimulation of food intake. 636
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success? 636
MPTP: advances from an evergreen neurotoxin 627
Changes in GAD67 and peptides mRNA levels in specific populations of striatal efferent neurons following priming with dopamine agonists in 6-OHDA lesioned rats 620
Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice 615
Alterazioni nei livelli striatali di RNAm della GAD67, dinorfina e enkefalina, in seguito a priming con agonisti dopaminergici nel modello di morbo di parkinson della 6-ohda 607
Expression offunctional leptin receptors in rodent leydig cells 592
Differential effect of priming with dopamine agonists on mrna for GAD-67, dynorphin and enkephalin in 6-OHDA lesioned rats 590
Nanocrystals as an effective strategy to improve Pomalidomide bioavailability in rodent 583
Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata 581
Different patterns of behavior and gene expression induced by chronic L-DOPA and A2A antagonists plus L-DOPA treatments in 6-hydroxydopamine lesioned rats 578
Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease 555
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease 523
Totale 161.633
Salva come PNG Salva come JPEG
Categoria #
all - tutte 207.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 207.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116.261 0 0 0 0 0 4.380 3.302 2.350 1.186 1.926 1.735 1.382
2021/20228.062 1.090 465 470 646 618 417 493 409 759 912 869 914
2022/202314.219 1.057 1.774 1.717 1.115 966 1.524 863 1.000 1.004 1.130 1.452 617
2023/202413.719 605 638 656 772 1.377 2.227 2.265 999 562 976 1.216 1.426
2024/202520.375 2.774 3.665 4.834 2.900 1.350 1.690 1.859 175 258 249 256 365
2025/20262.944 461 274 760 574 479 396 0 0 0 0 0 0
Totale 167.543